pfizer glp-1 agonist Sciwind Biosciences partners with China to commercialise Biased in China in $495 M deal Pfizer Phase IIb Data Support

The studys European ancestry focus limits generalizability

This review summarizes current evidence on the nutritional implications of GLP1-based pharmacotherapy in adults with obesity, including common gastrointestinal adverse events, reduced energy intake, potential macro and micronutrient inadequacies, and risks of lean mass loss

Innovations in drug delivery methods and sustained R&D investments further enhance market potential

Gastroparesis, also known as stomach paralysis, is not typically life-threatening, but complications from the condition can be fatal.

GLP-1 drug interactions may affect medication absorption